Hoshimoto Sojun, Hishinuma Shoichi, Shirakawa Hirofumi, Tomikawa Moriaki, Ozawa Iwao, Hoshi Nobuo, Hoshi Sayuri, Hirabayashi Kaoru, Ogata Yoshiro
Department of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center, Japan.
Department of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center, Japan.
Pancreatology. 2017 Jan-Feb;17(1):109-114. doi: 10.1016/j.pan.2016.11.001. Epub 2016 Nov 7.
The prognostic significance of intraoperative peritoneal washing cytology (IPWC) in pancreatic ductal adenocarcinoma (PDAC) remains controversial, and the treatment strategy for PDAC patients with positive cytology has not been established.
The objective of this study was to evaluate the clinical significance of IPWC in PDAC patients.
This study included a retrospective cohort of 166 patients with curatively resected PDAC who underwent IPWC.
Overall, 17 patients (10%) had positive cytology (CY+), and 149 (90%) patients were negative (CY-). Tumor location in the pancreatic body and/or tail and pancreatic anterior capsular invasion were independent predictors of a CY+ status (P = 0.012 and 0.041, respectively). The initial recurrence occurred at the peritoneum with a significantly higher frequency in CY+ patients (50%) than in CY- patients (12%) (P = 0.003). The median overall survival (OS) for CY+ patients was 12 months. The OS rates at 1 and 3 years were significantly higher for CY- patients (75.1% and 35.3%, respectively) versus CY+ patients (47.1% and 17.6%, respectively; P = 0.012). However, one CY+ patient survived for 66 months, and another two CY+ patients have survived for more than three years after surgery without evidence of peritoneal recurrence. In the multivariate analysis, the independent predictors of OS were a CY+ status, lymph node metastasis, and adjuvant chemotherapy.
This study demonstrates that positive IPWC predicts early peritoneal recurrence and a poor prognosis for PDAC patients. However, a small but not insignificant subset of CY+ patients with PDAC may avoid peritoneal carcinomatosis.
术中腹腔冲洗细胞学检查(IPWC)在胰腺导管腺癌(PDAC)中的预后意义仍存在争议,且细胞学检查阳性的PDAC患者的治疗策略尚未确立。
本研究的目的是评估IPWC在PDAC患者中的临床意义。
本研究纳入了166例行根治性切除的PDAC患者的回顾性队列,这些患者均接受了IPWC检查。
总体而言,17例患者(10%)细胞学检查阳性(CY+),149例患者(90%)为阴性(CY-)。胰体和/或胰尾的肿瘤位置以及胰腺前包膜侵犯是CY+状态的独立预测因素(分别为P = 0.012和0.041)。CY+患者初始复发部位在腹膜的频率显著高于CY-患者(50%比12%)(P = 0.003)。CY+患者的中位总生存期(OS)为12个月。CY-患者1年和3年的OS率显著高于CY+患者(分别为75.1%和35.3%)与CY+患者(分别为47.1%和17.6%;P = 0.012)。然而,1例CY+患者存活了66个月,另外2例CY+患者术后存活超过3年且无腹膜复发迹象。在多变量分析中,OS的独立预测因素为CY+状态、淋巴结转移和辅助化疗。
本研究表明,IPWC阳性预示着PDAC患者早期腹膜复发和预后不良。然而,一小部分但并非微不足道的CY+ PDAC患者可能避免腹膜癌转移。